ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · IEX Real-Time Price · USD
8.44
-0.62 (-6.84%)
At close: Apr 18, 2024, 4:00 PM
8.40
-0.04 (-0.47%)
Pre-market: Apr 19, 2024, 7:04 AM EDT
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for ARS Pharmaceuticals stock have an average target of 18.5, with a low estimate of 18 and a high estimate of 19. The average target predicts an increase of 119.19% from the current stock price of 8.44.
Analyst Consensus: Buy
* Price targets were last updated on Mar 11, 2024.
Analyst Ratings
The average analyst rating for SPRY stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $19 | Buy | Reiterates | $19 | +125.12% | Mar 11, 2024 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $6 → $18 | Hold → Buy | Upgrades | $6 → $18 | +113.27% | Mar 5, 2024 |
| Wedbush | Wedbush | Buy Maintains $5 → $13 | Buy | Maintains | $5 → $13 | +54.03% | Nov 13, 2023 |
| Wedbush | Wedbush | Buy Maintains $15 → $5 | Buy | Maintains | $15 → $5 | -40.76% | Sep 21, 2023 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Sep 20, 2023 |
Financial Forecast
Revenue This Year
5.45M
from 30.00K
Increased by 18,056.67%
Revenue Next Year
60.87M
from 5.45M
Increased by 1,017.57%
EPS This Year
-0.62
from -0.57
EPS Next Year
-0.54
from -0.62
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 8.4M | 67.2M | 175.8M | 321.7M | 466.9M |
| Avg | 5.4M | 60.9M | 170.8M | 198.3M | 314.9M |
| Low | 2.6M | 54.3M | 164.1M | 80.9M | 169.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 27,900.0% | 1,133.7% | 188.7% | 88.4% | 135.4% |
| Avg | 18,056.7% | 1,017.6% | 180.5% | 16.2% | 58.7% |
| Low | 8,653.3% | 896.0% | 169.5% | -52.7% | -14.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.60 | -0.48 | - |
| Avg | -0.62 | -0.54 | - |
| Low | -0.64 | -0.59 | - |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.